POLBF (Poolbeg Pharma) Loans Receivable: $0.00 Mil (As of Dec. 2025)


What is Poolbeg Pharma Loans Receivable?

Poolbeg Pharma POLBF Loans Receivable is $0.00 Mil as of Dec. 2025. The stock has 1 warning sign investors should review.

Poolbeg Pharma's Loans Receivable for the quarter that ended in Dec. 2025 was $0.00 Mil.

Poolbeg Pharma Loans Receivable Historical Data

* Premium members only.

The historical data trend for Poolbeg Pharma's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Poolbeg Pharma Loans Receivable Chart

Poolbeg Pharma Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Loans Receivable
0.00 0.00 0.00 0.00 0.00

Poolbeg Pharma Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Loans Receivable Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

Poolbeg Pharma Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.

Frequently Asked Questions Learn more about Loans Receivable →
What does a Loans Receivable of $0.00 Mil mean?
Poolbeg Pharma (POLBF) has a Loans Receivable of $0.00 Mil as of Dec. 2025. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on Poolbeg Pharma and its competitors.
Is Poolbeg Pharma's Loans Receivable too high?
Poolbeg Pharma's current Loans Receivable is $0.00 Mil.
How does Poolbeg Pharma's Loans Receivable compare to VRTX and REGN?
Poolbeg Pharma's Loans Receivable of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Loans Receivable for a Biotechnology company?
A good Loans Receivable depends on the Biotechnology industry context. However, Loans Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Loans Receivable mean?
A high Loans Receivable can signal that a stock is expensive relative to its fundamentals. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on Poolbeg Pharma and its competitors. Poolbeg Pharma's current Loans Receivable is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Poolbeg Pharma stock overvalued right now?
Poolbeg Pharma (POLBF) has a current Loans Receivable of $0.00 Mil. The current Loans Receivable is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Loans Receivable calculated?
Loans Receivable is calculated from a company's financial statements. For Poolbeg Pharma (POLBF), the current Loans Receivable is $0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Poolbeg Pharma Business Description

Other Exchanges POLB:UK7JN:Germany
Address 20 St. Andrew Street, The Clubhouse Holborn, London, GBR, EC4A 3AG
Poolbeg Pharma PLC is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company's main asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). The group is also advancing the development of a patient-friendly therapy for obesity with an oral encapsulated GLP-1, offering a differentiated approach within one of the world's markets. It is focused on partnering its high-value programmes that are targeting large markets and addressing critical unmet medical needs.